Waystar (WAY) is reportedly exploring options which include a sale, according to reports

Waystar sits in healthcare payments software, a segment where sponsor-backed assets have historically attracted both private equity take-privates and strategic buyers looking to consolidate revenue-cycle technology, so the natural bidder universe splits between financial sponsors comfortable with leveraged software cash flows and strategics seeking cross-sell into provider networks. The recent listing history matters here: recently public sponsor-backed names that field sale interest have often traded on the gap between the takeout speculation and the still-fresh IPO reference valuation, with controlling holders' willingness to sell at a given level the binding constraint. The distinction worth drawing is between a genuine auction and an options review that ends in a minority investment or refinancing, since only the former carries the control premium the stock will begin to price. Tells from here are whether the company confirms a formal review, whether named bankers surface, and whether PE peers in the healthcare IT space see sympathy bid interest on read-across. As an unconfirmed report, positioning risk runs both ways on denial.